Shanghai Pharma, Vitaco deal needs New Zealand investment office clearance

​The takeover of Australia-listed vitamin producer Vitaco by Shanghai Pharmaceuticals and its private equity partner, Primavera Capital, needs clearance from New Zealand’s Overseas Investment Office.​The takeover of Australia-listed vitamin producer Vitaco...

Already a subscriber? Click here to view full article